Actively Recruiting
Efficacy of Spironolactone Combined With Antihypertensive Drugs in Patients With Primary Aldosteronism
Led by Third Military Medical University · Updated on 2025-08-22
350
Participants Needed
1
Research Sites
208 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this observational study is to learn about the optimal dose of spironolactone treatment and the long-term outcomes on cardiovascular and cerebrovascular events in patients with lateralized PA who are unwilling to undergo surgery. The main question it aims to answer is: 1. What is the long-term effect of spironolactone treatment for lateralized PA? 2. What is the optimal dose of spironolactone treatment for the relief of renin inhibition in patients with lateralized PA? Participants will receive spironolactone treatment as part of their regular medical care for more than 12 months, and their clinical indicators, including blood pressure, biochemical remission, cardiovascular and renal damage, and the incidence of cardiovascular and cerebrovascular events, will be analyzed.
CONDITIONS
Official Title
Efficacy of Spironolactone Combined With Antihypertensive Drugs in Patients With Primary Aldosteronism
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or female, aged 30 to 65 years
- Diagnosed with primary aldosteronism confirmed by positive screening and saline suppression tests, and lateralization confirmed by adrenal venous sampling
- Hypertension defined as office blood pressure ≥ 140/90 mmHg, or 24-hour ambulatory blood pressure showing average ≥ 130/80 mmHg, daytime blood pressure ≥ 135/85 mmHg, or nighttime blood pressure ≥ 120/70 mmHg
- Patients with unilateral aldosterone-producing adenoma who decline surgery or non-adenoma unilateral PA confirmed by adrenal venous sampling
- Provided written informed consent to participate in the study
You will not qualify if you...
- Hyperkalemia
- Renal impairment or history of kidney disease: serum creatinine above 1.5 times upper limit of normal, dialysis, or nephrotic syndrome
- Other confirmed secondary hypertension causes such as pheochromocytoma, Cushing's syndrome, thyroid or parathyroid disorders, acromegaly, renovascular disease, aortic disorders, chronic alcoholism, or drug dependence
- Adrenal insufficiency
- Heart failure classified as NYHA class II-IV or stroke
- Acute infection, cancer, severe arrhythmia, psychiatric disorders, or drug/alcohol abuse
- Significant liver dysfunction or history of liver disease: AST or ALT more than twice upper limit of normal, cirrhosis, hepatic encephalopathy, esophageal varices, or portosystemic shunt
- Pregnancy or lactation
- Participation in another clinical trial in the past 3 months
- Inability to complete follow-up
- Refusal to provide informed consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Daping Hospital, Army Medical Center of PLA
Chongqing, Chongqing Municipality, China, 400042
Actively Recruiting
Research Team
Z
Zhencheng Yan, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here